Cardiovascular adverse events and prognosis in patients with haematologic malignancies and breast cancer receiving anticancer agents: Kurume-CREO Registry insights
An erratum to this article was published (Eur J Prev Cardiol, 21 Dec 2023 ↗)
Authors' conclusion
This study revealed that 16-38% of patients with haematologic malignancies and breast cancer developed CTR-CVT during follow-up, in which patients with high/very high risk were well predicted by the HFA-ICOS risk assessment tool.
Study context
- Population
- Patients aged ≥20 years with haematologic malignancies or breast cancer receiving anticancer agents, Kurume University Hospital, October 2016 to August 2021
- Participants
- 486 patients
- Exposure
- Leukaemia vs Malignant lymphoma vs Multiple myeloma vs Breast cancer
- Outcome
- CV adverse events, CTCAE v4.0 Grade ≥2
Methodological detailssingle-centre, observational
- Single-centre
- Observational
Main finding
As reported in the abstract
CV adverse events
Observational data: associations, not effects.
Secondary outcomes
Cardiovascular (CV) death · during follow-up
- CV death
- 4 (0.8%)
Original publication
Cardiovascular adverse events and prognosis in patients with haematologic malignancies and breast cancer receiving anticancer agents: Kurume-CREO Registry insights. Eur J Prev Cardiol. Published 23 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →